Index RUT
P/E -
EPS (ttm) -2.58
Insider Own 19.40%
Shs Outstand 48.08M
Perf Week 43.40%
Market Cap 162.13M
Forward P/E -
EPS next Y -1.77
Insider Trans 0.92%
Shs Float 38.77M
Perf Month -4.26%
Income -123.46M
PEG -
EPS next Q -0.54
Inst Own 54.38%
Short Float 13.97%
Perf Quarter 75.98%
Sales 0.00M
P/S -
EPS this Y 25.09%
Inst Trans 10.10%
Short Ratio 9.76
Perf Half Y 129.25%
Book/sh 1.47
P/B 2.29
EPS next Y 8.17%
ROA -71.49%
Short Interest 5.42M
Perf Year -5.60%
Cash/sh 2.32
P/C 1.45
EPS next 5Y -
ROE -98.37%
52W Range 1.24 - 4.07
Perf YTD 36.99%
Dividend Est. -
P/FCF -
EPS past 5Y -25.30%
ROI -172.65%
52W High -17.16%
Beta 1.21
Dividend TTM -
Quick Ratio 4.11
Sales past 5Y -56.91%
Gross Margin -
52W Low 171.77%
ATR (14) 0.34
Dividend Ex-Date -
Current Ratio 4.11
EPS Y/Y TTM 5.54%
Oper. Margin 0.00%
RSI (14) 60.41
Volatility 19.73% 11.82%
Employees 65
Debt/Eq 0.03
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 11.50
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 10.43%
Payout -
Rel Volume 7.36
Prev Close 2.26
Sales Surprise -
EPS Surprise 29.34%
Sales Q/Q -
Earnings Mar 26 AMC
Avg Volume 554.69K
Price 3.37
SMA20 17.23%
SMA50 21.53%
SMA200 46.52%
Trades
Volume 4,081,676
Change 49.45%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-15-22 Initiated
JMP Securities
Mkt Outperform
$17
May-05-22 Downgrade
Credit Suisse
Outperform → Neutral
$35 → $5
Mar-21-22 Initiated
H.C. Wainwright
Buy
$25
Oct-15-21 Resumed
BTIG Research
Buy
$68
Jun-28-21 Initiated
ROTH Capital
Buy
$75
May-05-21 Resumed
Credit Suisse
Outperform
$68
Apr-26-21 Resumed
Credit Suisse
Outperform
$68
Jan-11-21 Initiated
JP Morgan
Overweight
$45
Jan-11-21 Initiated
Jefferies
Buy
$51
Jan-11-21 Initiated
Credit Suisse
Outperform
$49
Jan-11-21 Initiated
BTIG Research
Buy
$47
Show Previous Ratings
Apr-24-24 04:35PM
Mar-27-24 10:07AM
07:56AM
(Thomson Reuters StreetEvents)
Mar-26-24 09:54PM
05:33PM
04:01PM
Loading…
04:01PM
Mar-19-24 08:00AM
Mar-07-24 08:00AM
Dec-20-23 08:00AM
Dec-13-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
04:01PM
Loading…
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
06:48AM
Aug-02-23 11:31AM
(Thomson Reuters StreetEvents)
Aug-01-23 04:01PM
Jul-25-23 08:00AM
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
08:00AM
Loading…
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
(Thomson Reuters StreetEvents)
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
(Simply Wall St.) +10.32%
Nov-08-22 08:00AM
Nov-04-22 11:15AM
09:08AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
Sep-12-22 10:08AM
Aug-18-22 06:39AM
Aug-09-22 07:25PM
04:05PM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jun-04-22 08:12AM
Jun-01-22 04:05PM
May-04-22 04:01PM
Apr-08-22 08:00AM
Mar-01-22 06:00AM
Feb-07-22 05:38PM
Jan-10-22 04:05PM
Dec-21-21 09:00AM
Dec-11-21 06:34AM
Nov-15-21 05:09PM
Oct-04-21 10:56AM
Sep-29-21 08:03AM
Sep-12-21 08:49AM
Aug-13-21 05:54PM
Jun-14-21 02:03AM
(Simply Wall St.) -19.76%
May-12-21 06:26PM
Mar-16-21 01:59AM
Dec-18-20 04:00PM
Dec-16-20 05:34PM
04:52PM
Dec-15-20 07:59PM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCBRINN SYLVIA Director Dec 26 '23 Buy 2.33 4,000 9,320 15,125 Dec 26 07:43 PM SHORT JAY M PHD Chief Executive Officer Dec 20 '23 Buy 2.14 50,000 106,910 1,439,283 Dec 20 06:27 PM STEINMAN LAWRENCE Director Dec 19 '23 Buy 2.05 20,000 41,048 38,459 Dec 19 08:24 PM Vasquez Christian See Remarks Dec 19 '23 Buy 2.04 7,495 15,262 115,659 Dec 19 04:33 PM MCBRINN SYLVIA Director Sep 08 '23 Buy 2.54 2,000 5,080 11,125 Sep 13 06:55 PM
Index -
P/E -
EPS (ttm) -13.31
Insider Own 28.67%
Shs Outstand 1.04M
Perf Week -1.27%
Market Cap 7.28M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 0.74M
Perf Month -3.45%
Income -15.96M
PEG -
EPS next Q -
Inst Own 1.19%
Short Float 1.34%
Perf Quarter -0.57%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -
Short Ratio 2.62
Perf Half Y -3.31%
Book/sh 22.46
P/B 0.31
EPS next Y -
ROA -43.50%
Short Interest 0.01M
Perf Year 0.00%
Cash/sh 15.70
P/C 0.45
EPS next 5Y -
ROE -47.07%
52W Range 5.25 - 17.40
Perf YTD -5.41%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -68.22%
52W High -59.77%
Beta 0.86
Dividend TTM -
Quick Ratio 6.34
Sales past 5Y -33.33%
Gross Margin -
52W Low 33.23%
ATR (14) 0.30
Dividend Ex-Date -
Current Ratio 6.34
EPS Y/Y TTM -20.79%
Oper. Margin 0.00%
RSI (14) 45.22
Volatility 0.83% 3.82%
Employees 8
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 40.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -23.32%
Payout -
Rel Volume 0.04
Prev Close 6.92
Sales Surprise -
EPS Surprise -
Sales Q/Q -100.00%
Earnings -
Avg Volume 3.79K
Price 7.00
SMA20 -6.77%
SMA50 -5.18%
SMA200 -16.41%
Trades
Volume 136
Change 1.16%
Index -
P/E -
EPS (ttm) -28.80
Insider Own 3.20%
Shs Outstand 0.53M
Perf Week 9.34%
Market Cap 1.05M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 0.52M
Perf Month -5.24%
Income -19.94M
PEG -
EPS next Q -
Inst Own 6.91%
Short Float 3.29%
Perf Quarter -51.06%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -
Short Ratio 0.16
Perf Half Y -75.90%
Book/sh -0.24
P/B -
EPS next Y -
ROA -98.29%
Short Interest 0.02M
Perf Year -90.48%
Cash/sh 3.74
P/C 0.53
EPS next 5Y -
ROE -355.47%
52W Range 1.33 - 27.93
Perf YTD -50.94%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -92.88%
Beta -
Dividend TTM -
Quick Ratio 0.72
Sales past 5Y 0.00%
Gross Margin -
52W Low 49.62%
ATR (14) 0.33
Dividend Ex-Date -
Current Ratio 0.72
EPS Y/Y TTM 82.38%
Oper. Margin 0.00%
RSI (14) 44.81
Volatility 11.02% 17.12%
Employees 4
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 1520.00
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 78.93%
Payout -
Rel Volume 0.25
Prev Close 2.15
Sales Surprise -
EPS Surprise 84.62%
Sales Q/Q -
Earnings -
Avg Volume 106.93K
Price 1.99
SMA20 -1.56%
SMA50 -28.35%
SMA200 -72.86%
Trades
Volume 26,969
Change -7.44%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-15-21 Initiated
Maxim Group
Buy
$11
Mar-14-24 08:30AM
Feb-26-24 07:00AM
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
08:46AM
Loading…
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
08:00AM
Loading…
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
08:00AM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
08:30AM
Loading…
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
02:26PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
08:10AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
08:00AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Woody James N. Chief Executive Officer Dec 15 '23 Buy 0.19 25,000 4,700 66,888 Dec 18 04:15 PM Feldmann Marc Director Dec 15 '23 Sale 0.19 25,000 4,700 115,497 Dec 18 04:15 PM STEINMAN LAWRENCE Director Jun 01 '23 Buy 1.23 18,000 22,068 48,129 Jun 02 08:00 AM McGovern Jr. Donald A. Director May 31 '23 Buy 1.15 10,000 11,470 30,099 Jun 01 08:00 AM McGovern Jr. Donald A. Director May 19 '23 Buy 1.16 5,000 5,800 20,099 May 22 08:00 AM Woody James N. Chief Executive Officer May 18 '23 Buy 1.03 40,000 41,200 41,888 May 18 04:40 PM McGovern Jr. Donald A. Director May 18 '23 Buy 1.05 10,000 10,500 15,099 May 22 08:00 AM Marrone Pamela G Director May 18 '23 Buy 1.06 7,082 7,507 12,469 May 19 08:45 AM Pamir Ozan CFO May 18 '23 Buy 1.01 5,162 5,214 8,983 May 19 08:30 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite